8.60
-0.365(-4.07%)
Currency In USD
| Previous Close | 8.96 |
| Open | 9 |
| Day High | 9.01 |
| Day Low | 8.53 |
| 52-Week High | 13.16 |
| 52-Week Low | 6.19 |
| Volume | 236,751 |
| Average Volume | 1.45M |
| Market Cap | 483.85M |
| PE | 18.29 |
| EPS | 0.47 |
| Moving Average 50 Days | 9.14 |
| Moving Average 200 Days | 9.15 |
| Change | -0.37 |
If you invested $1000 in Zevra Therapeutics, Inc. (ZVRA) 10 years ago, it would be worth $29.15 as of January 02, 2026 at a share price of $8.595. Whereas If you bought $1000 worth of Zevra Therapeutics, Inc. (ZVRA) shares 5 years ago, it would be worth $822.49 as of January 02, 2026 at a share price of $8.595.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC)
GlobeNewswire Inc.
Dec 29, 2025 12:30 PM GMT
CELEBRATION, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
GlobeNewswire Inc.
Dec 02, 2025 12:30 PM GMT
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment o
Zevra Therapeutics, Inc. Announces CFO Transition
GlobeNewswire Inc.
Nov 20, 2025 9:05 PM GMT
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Fin